Search

YoungEHA

Welcome to YoungEHA!As a junior member of EHA, you are part of the YoungEHA family.

Read more

How to apply for an EHA Research Grant

On this page, we explain all of the actions you'll need to take when submitting a grant application. You can also get a basic overview of the process in our EHA Research Grants diagram.

Read more

Research & Mentoring

One of EHA’s key pillars is investing in future leaders in hematology.

Read more

EHA-RHS-ROHS Hematology Tutorial 2021

EHA in collaboration with the National Hematological Society (RHS) and the Russian Onco-Hematology Society (ROHS) are closely monitoring the developments concerning the Coronavirus (COVID-19), as our priorities lie with the health and safety of our participants and partners.

Read more

EHA-SWG Scientific Meeting on Systemic Risk of Thrombosis or Bleeding

Meeting chairs, Carlo Balduini and Anna Falanga

The meeting was well attended by more than 100 participants coming from over 20 different countries

Delegate: Great meeting.

Read more

EMA Issues Call for Expressions of Interest for Drug Safety Studies

The purpose of this call is to enable the EMA to obtain fast and reliable answers to questions on safety or benefit/risk concerns, and ultimately facilitating regulatory decision-making.

Read more

EHA Lymphoma Group

The EHA Lymphoma Group (EHA LyG) is a specialized working group that was established in 2014.

Read more

EU calls for proposal 2023

IntroductionHorizon Europe is the research and innovation programme of the EU for the period 2021-2027. The programme facilitates research collaboration and strengthens the impact of R&I in developing, supporting and implementing EU policies while tackling global challenges.

Read more

Addition of obinutuzumab (GA101) or rituximab to chlorambucil improves outcomes for elderly patients with chronic lymphocytic leukemia (CLL) and co-existing medical conditions (comorbidities)

CLL is the most common leukemia in the western world. Many CLL patients are elderly and have comorbidities rendering them ineligible for aggressive standard treatments.

Read more